Exactly. The management has no good control on costs. If we just look at cv sciences. They have much higher valuation because their sales growth come with much more controllable costs. Their profit grow even faster than revenue, while EXL back to loss with sales growth.
Ann: Quarterly Report and Appendix 4C, page-10
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EXL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.002(33.3%) |
Mkt cap ! $6.605M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $2.103K | 475.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 7670493 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 924824 | 4 |
View Market Depth
| Last trade - 14.04pm 29/11/2024 (20 minute delay) ? |
| EXL (ASX) Chart |
